Background:Astegolimab, a human IgG2mAb, selectively inhibits the IL-33 receptor, ST2. Approved biologic therapies for severe asthma mainly benefit patients with elevated blood eosinophils type 2-high, but limited options are available for patients with low blood eosinophils type 2-low.
Alternative Names:AMG-282, MSTT-1041A, RG-6149, RO-7187807,